In cells with loss of function mutations associated with breast cancer susceptibility genes BRCA1 or 2, inhibition of PARP was demonstrated to be synthetically lethal (Bryant et al., 2005; Farmer et al., 2005). This evidence concerns the gene BRCA1 and breast carcinoma.